ParkHa raises $2M in registered direct offering

What's the deal? ParkHa Biological Technology has entered into a securities purchase agreement with several investors for a $2M private placement. The offering consists of up to 1,133,332 Class A ordinary shares and pre-funded warrants to purchase up to 200,000 additional Class A ordinary shares, priced at $1.50 per share and pre-funded warrant. D. Boral Capital is acting as sole placement agent.

The company said it intends to use the net proceeds for general corporate and working capital purposes.

What could go wrong? A $2M raise at $1.50 per share is modest, and reliance on warrants suggests the company may struggle to attract capital at higher price points. Using proceeds for general working capital — rather than a specific growth initiative — can signal a company is raising to keep the lights on rather than to scale.

The signal: ParkHa Biological's $2M registered direct offering at $1.50 per share, with pre-funded warrants baked into the structure, fits a well-worn pattern among early-stage life sciences companies turning to dilutive private placements when public market valuations offer little leverage. The use of proceeds for general working capital rather than a defined milestone — such as a clinical trial or product launch — suggests this is a bridge raise, underscoring how capital-constrained smaller biotech firms remain in the current funding environment.